Bain Capital Life Sciences Investors, LLC Long-Term Concentrated

CIK: 0001703031 · Show all filings

Period: Q4 2018 (← Previous) (Next →)

Filing Date: Feb 14, 2019

Total Value ($000): $292,636 (100.0% shares, 0.0% debt)

Holdings (6)

— DICERNA PHARMACEUTICALS INC 32.6%

Value ($000) $95,464 Shares 8,930,237 Est. Cost $9.03 Unrealized —

IFRX INFLARX NV 21.9%

Value ($000) $64,189 Shares 1,764,888 Est. Cost $17.97 Unrealized +71.3%

— SOLID BIOSCIENCES INC 18.2%

Value ($000) $53,317 Shares 1,989,444 Est. Cost $7.50 Unrealized —

— APTINYX INC 12.6%

Value ($000) $36,803 Shares 2,225,092 Est. Cost $24.17 Unrealized —

REPL REPLIMUNE GROUP INC 9.7%

Value ($000) $28,390 Shares 2,838,968 Est. Cost $17.53 Unrealized -22.9%

— MARINUS PHARMACEUTICALS INC 4.9%

Value ($000) $14,473 Shares 5,042,735 Est. Cost $7.04 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	DICERNA PHARMACEUTICALS INC	8,930,237	$95,464	32.6%	$9.03	—	COM	253031108
IFRX	INFLARX NV	1,764,888	$64,189	21.9%	$17.97	+71.3%	COM	N44821101
—	SOLID BIOSCIENCES INC	1,989,444	$53,317	18.2%	$7.50	—	COM	83422E105
—	APTINYX INC	2,225,092	$36,803	12.6%	$24.17	—	COM	03836N103
REPL	REPLIMUNE GROUP INC	2,838,968	$28,390	9.7%	$17.53	-22.9%	COM	76029N106
—	MARINUS PHARMACEUTICALS INC	5,042,735	$14,473	4.9%	$7.04	—	COM	56854Q101